Defence Therapeutics Inc (DTC)

Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership DiscussionsJune 17, 2026 3:15 AM
NewsfileMontreal, Quebec--(Newsfile Corp. - June 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce its participation in the BIO International Convention 2026, taking place June 22-25 in San Diego, California.Defence's team will be available throughout the conference to meet with pharmaceutical and biotechnology companies, investors, and potential strategic collaborators interested in exploring partnership opportunities involving Defence's proprietary Accum® platform.Accum® is designed to enhance intracellular delivery by promoting endosomal escape and improving delivery to target cellular compartments. The platform is being applied across multiple therapeutic modalities, including antibody-drug conjugates (ADCs) and radiopharmaceutical drug conjugates (RDCs), where efficient intracellular delivery remains a critical challenge.Defence is actively seeking partnerships with innovative pharmaceutical and biotechnology companies, biosimilar developers, and technology providers interested in leveraging Accum® to unlock additional value from their therapeutic programs. Partnership opportunities include the development of novel Accum®-enabled ADCs, enhancement of biosimilar products, revitalization of existing or discontinued assets, and co-development of advanced delivery and linker technologies. Accum® can be incorporated into ADC programs without restarting the engineering process, enabling integration at any stage of development, from discovery through clinical evaluation."BIO International Convention is one of the most important gatherings for the global biotechnology industry, bringing together innovators, investors, and pharmaceutical leaders from around the world," said Sébastien Plouffe, Chief Executive Officer of Defence Therapeutics. "For Defence, it provides a unique opportunity to showcase the potential of our Accum® platform and engage with organizations seeking innovative approaches to improve the delivery and effectiveness of advanced therapeutics. We look forward to meeting with potential partners and exploring opportunities to create value through collaborations."Companies interested in scheduling a meeting with Defence during BIO 2026 are encouraged to contact the Company in advance through the BIO Partnering platform or by reaching out directly to the Defence team at info@defencetherapeutics.com.About Defence Therapeutics:Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting-edge science and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.For further information:Defence Therapeutics
Sebastien Plouffe
CEO, Founder and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.comCautionary Statement Regarding "Forward-Looking" InformationThis release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301748 Original: Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions

Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of DirectorsJune 3, 2026 3:15 AM
NewsfileMontreal, Quebec--(Newsfile Corp. - June 3, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John Beaver to its Board of Directors. Dr. Beaver brings more than two decades of leadership experience across global pharmaceutical and biotechnology organizations.Dr. Beaver has held senior leadership positions at several leading biopharmaceutical companies, including Biogen, AbbVie, and GlaxoSmithKline, where he contributed to the advancement of innovative therapeutic programs across multiple disease areas. His extensive experience spans translational medicine, biomarker discovery and development, and clinical pharmacology, providing him with a deep understanding of how innovative therapeutics are advanced, evaluated, and strategically developed within global pharma organizations.Most recently, Dr. Beaver served as Vice President and Head of Global Biomarker Discovery & Development at Biogen, where he led global biomarker and translational development activities supporting approximately 48 pipeline programs. During his tenure, he contributed to biomarker-driven development strategies associated with industry-first FDA accelerated approvals in Alzheimer's disease and ALS, while also serving on several R&D leadership, governance, and partnership committees.Prior to Biogen, Dr. Beaver held senior leadership roles at AbbVie, where he served as Head of Translational Imaging and was recognized as a Volwiler Research Fellow for his scientific contributions. Earlier in his career, he was a Senior Imaging Scientist at GlaxoSmithKline's Clinical Imaging Centre at Imperial College London's Hammersmith Hospital campus and later served as Director of Imaging at Maccine in Singapore. He also conducted human brain imaging research as a postdoctoral fellow with the UK Medical Research Council at the University of Cambridge.Dr. Beaver is currently the Co-Founder and Chief Executive Officer of a stealth-mode biotechnology company based in the Greater Boston area, where he is leveraging his extensive experience in translational science, biomarker innovation, and strategic drug development to advance next-generation therapeutic approaches."We are very proud to welcome Dr. John Beaver to Defence's Board of Directors," said Sébastien Plouffe, CEO of Defence Therapeutics. "John extensive pharmaceutical industry experience will be highly valuable as Defence continues advancing its ACCUM® platform and expanding its development and partnership activities.""I am excited to join Defence Therapeutics' Board of Directors and support the Company during this important stage of growth," said Dr. John Beaver. "Defence's ACCUM® technology has the potential to significantly enhance intracellular delivery and unlock new possibilities for next-generation therapeutics. I look forward to supporting the Company's strategic growth and helping strengthen its strategic and pharmaceutical partnership initiatives."The company has granted 150,000 incentive stock options to Dr. Beaver, in accordance with the terms and conditions of Defence's omnibus incentive plan. The options are vested immediately and exercisable at a price of 60 cents per share for a period of five years from the date of grant.Defence Therapeutics is actively advancing its proprietary ACCUM® platform across multiple therapeutic applications, including ADCs and radiopharmaceuticals, with the objective of improving intracellular delivery, therapeutic efficacy, and overall treatment outcomes. To learn more or explore partnering opportunities, please visit Defence Therapeutics or contact info@defencetherapeutics.com.About Defence Therapeutics:
Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.For further information:
Defence Therapeutics
Sebastien Plouffe
CEO, Founder and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.comCautionary Statement Regarding "Forward-Looking" InformationThis release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299920 Original: Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors

Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of DirectorsJune 1, 2026 3:15 AM
NewsfileMontreal, Quebec--(Newsfile Corp. - June 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John Lambert to its Board of Directors, effective immediately. Dr. Lambert brings more than four decades of scientific leadership and pioneering expertise in the development of antibody-drug conjugates ("ADCs"), further strengthening Defence's strategic capabilities as the Company advances its ACCUM®-enabled ADC platform and partnership programs. Dr. Lambert is internationally recognized as one of the leading experts in the ADC field. He previously served in multiple senior scientific and executive leadership roles at ImmunoGen, including Chief Scientific Officer, Executive Vice President of Research, and member of the Executive Committee. During his tenure, scientists at ImmunoGen developed ADC technologies that ultimately contributed to the Genentech/Roche therapy KADCYLA®, approved in 2013 for HER2-positive breast cancer. The company also discovered the anti-CD38 antibody that became Sanofi's SARCLISA® and advanced several ADC molecules into clinical development, including ELAHERE®, approved for platinum-resistant ovarian cancer. ImmunoGen was subsequently acquired by AbbVie in 2024.Prior to joining ImmunoGen in 1987, Dr. Lambert was among the first scientists recruited to the Dana-Farber Cancer Institute at Harvard Medical School to work on ImmunoGen-funded programs dedicated to developing ADCs and immunotoxins as anti-cancer therapeutics, at a time when the field was still in its infancy.Dr. Lambert's scientific career also includes training at some of the world's most respected academic institutions. He graduated from Christ's College, University of Cambridge (UK), with a degree in Natural Sciences before earning a Ph.D. in Biochemistry from the University of Cambridge in 1976, where he worked on the structure of glycolytic enzymes under the supervision of Professor Richard N. Perham. He subsequently completed postdoctoral research at the University of California, Davis, focusing on ribosome structure, and later at the University of Glasgow, Scotland, where he worked on the arom multienzyme complex.Since 2018, Dr. Lambert has advised numerous biotechnology companies and venture capital firms on ADC technologies, development strategies, and translational programs. He is the author or co-author of more than 130 peer-reviewed scientific publications and was elected Fellow of the American Institute for Medical and Biological Engineering (AIMBE) in 2016."We are extremely proud to welcome Dr. Lambert to Defence's Board of Directors," said Sébastien Plouffe, Chief Executive Officer of Defence Therapeutics. "John is one of the most respected pioneers in the ADC field and has contributed to the development of technologies and therapeutics that have had a major impact on cancer treatment worldwide. His scientific vision, leadership experience, and deep understanding of ADC development will be instrumental as Defence advances its ACCUM® platform and expands its ACCUM®-enabled ADC programs and partnerships. Having someone of John's caliber joining our Board is a tremendous validation of the potential of our technology.""I am excited to join Defence Therapeutics' Board of Directors at such an important time for the Company," said Dr. John Lambert. "Defence's ACCUM® technology represents a compelling and innovative approach to improving intracellular delivery and potentially enhancing the therapeutic performance of ADCs and other complex biologics. I look forward to working with the team and contributing to the continued advancement of the Company's technology and development programs."The company has granted 150,000 incentive stock options to Dr. Lambert, in accordance with the terms and conditions of Defence's omnibus incentive plan. The options are vested immediately and exercisable at a price of 58 cents per share for a period of five years from the date of grant.Defence Therapeutics is actively advancing its proprietary ACCUM® platform across multiple therapeutic applications, including ADCs and radiopharmaceuticals, with the objective of improving intracellular delivery, therapeutic efficacy, and overall treatment outcomes. To learn more or explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.About Defence Therapeutics:
Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.For further information:
Defence Therapeutics
Sebastien Plouffe
CEO, Founder and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com 
www.defencetherapeutics.comCautionary Statement Regarding "Forward-Looking" InformationThis release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299499 Original: Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors

Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis MeterissianMay 29, 2026 4:30 PM
NewsfileMontreal, Quebec--(Newsfile Corp. - May 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC)  ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, announces that Dr. Sarkis Meterissian resigned today from the Board of Directors of Defence to deepen engagement with the Company by joining the Scientific Advisory Board ("SAB"). Defence Therapeutics' current SAB is composed of Rob Leanna, PhD, Danny Chui, PhD and Brendan Hussey, PhD. The addition of Dr. Sarkis Meterissian, who is the Director of the Breast Center of the McGill University Health Centre ("MUHC") and the Head of the MUHC Breast Tumor Site Group, will strengthen the SAB by bringing direct expertise in the drugs and an acute understanding of patients needs. "I would like to thank Dr. Sarkis Meterissian for his five years on the Board of Directors. I am confident that his contribution to the SAB will be significant to Defence's success. Sarkis has been a strong believer in Defence's ACCUM® platform since day one, and now more than ever he wants to be more deeply involved in bringing it to the clinics for the benefit of patients," said Sébastien Plouffe, Chief Executive Officer of Defence Therapeutics.In addition, the Company wishes to announce that it has granted 150,000 incentive stock options to employees and consultants of the Company, in accordance with the terms and conditions of Defence's omnibus incentive plan. The options are vested immediately and exercisable at a price of 58 cents per share for a period of five years from the date of grant.About Defence Therapeutics:Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursuing cutting-edge science and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to the patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.For further information:
Defence Therapeutics
Sebastien Plouffe
CEO, Founder and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.comCautionary Statement Regarding "Forward-Looking" InformationThis release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299487 Original: Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian

Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing CapabilitiesMay 19, 2026 3:15 AM
NewsfileMontreal, Quebec--(Newsfile Corp. - May 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the expansion of internal capabilities to execute critical stages of its ACCUM®-enabled Antibody Drug Conjugates ("ADC") development pipeline. The Company has strengthened its purification, analytical characterization, conjugation development, and quality control ("QC") capabilities, while enhancing cellular testing and potency evaluation workflows within a more structured stage-gated framework to better support the advancement of its ADC partnership programs."By strengthening our internal QC, analytical, and conjugation capabilities, Defence is positioning itself to become a leading authority in the development and controlled manufacture of ACCUM®-enabled ADCs," said Mark Lambermon, PhD, Head of Quality & Operations at Defence Therapeutics. "Our focus is to establish robust, reproducible, and quality-driven processes that support the consistent generation of high-quality ACCUM®-ADC candidates for our partnership programs."To support the development of high-quality ACCUM®-enabled ADC candidates, the Company has acquired an FPLC system to improve purification workflows and the consistency of conjugated materials, while also advancing the evaluation of multiple conjugation methods, including site specific strategies. These efforts are guided by a structured framework designed to identify the most suitable conjugation approach for each partner ADC based on format, chemistry compatibility, Drug-to-Antibody Ratio ("DAR") profile, and developability characteristics such as stability and aggregation.In parallel, Defence Therapeutics is enhancing its analytical characterization and QC infrastructure through standardized analytical checkpoints, documentation practices, and reproducibility-focused processes designed to support reliable decision-making and partner-ready execution.The Company has also expanded its cellular testing capabilities with the addition of an Incucyte live-cell imaging platform designed to generate kinetic potency and mechanism-relevant cellular data designed to better assess the internalization, intracellular delivery, and cellular potency of ACCUM®-enabled ADC candidates. These capabilities are being integrated within a more structured stage-gated governance framework with clearly defined success criteria to support efficient lead candidate selection and downstream validation activities."As we continue to grow our ADC partnership activities, it is important that our internal capabilities evolve alongside the needs of our partners," said Amie Phinney, PhD, Defence Therapeutics' Strategy & Business Advisor. "These expanded capabilities strengthen our ability to tailor ACCUM® integration and support partner programs with greater confidence and precision.""By bringing key development and analytical capabilities in-house, we are strengthening our ability to rapidly evaluate and advance ACCUM®-enabled ADC candidates," said Sébastien Plouffe, Chief Executive Officer of Defence Therapeutics. "These expanded capabilities position us to accelerate our ADC partnership programs and support the development of more effective ADC therapies for patients."About Defence Therapeutics:Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.For further information:
Defence Therapeutics
Sebastien Plouffe
CEO, Founder and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.comCautionary Statement Regarding "Forward-Looking" InformationThis release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297634 Original: Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities

Defence Therapeutics Announces Grant of Restricted Stock UnitsApril 24, 2026 6:30 PM
NewsfileMontreal, Quebec--(Newsfile Corp. - April 24, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, wishes to announce that the board of directors of the Company approved the grant of 200,000 incentive restricted stock units ("RSUs") to Mr. Sebastien Plouffe, CEO and Director of the Company, vesting immediately. Each RSU entitles the holder thereof to receive one common share of the Company expiring on April 24, 2027, subject to the terms of the Omnibus Incentive Plan of the Company and applicable securities law hold periods. About Defence Therapeutics:Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.For further information:
Defence Therapeutics
Sebastien Plouffe
CEO, Founder and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.comCautionary Statement Regarding "Forward-Looking" InformationThis release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/294219
Original: Defence Therapeutics Announces Grant of Restricted Stock Units

Defence Therapeutics Announces Warrant Terms AmendmentMarch 20, 2026 6:00 PM
NewsfileMontreal, Quebec--(Newsfile Corp. - March 20, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce an amendment to the terms of a total of 800,000 Common Share purchase warrants (the "Warrants") originally issued as part of a private placement closed in 2024. The expiry date will be extended by 12 months and the exercise price will be repriced at $0.75 per Common Share, as follows:No. of 
Warrants:Original Expiry Date of Warrants:New Expiry Date of 
Warrants:Original Exercise Price of Warrants:New Exercise Price of 
Warrants:775,000October 30, 2026October 30, 2027$1.00$0.7525,000November 29, 2026November 29, 2027$1.00$0.75 None of the Warrants have been exercised as of the date hereof. All other terms of the Warrants will remain unchanged. In accordance with the requirements of the Canadian Securities Exchange, the terms of any warrants issued as compensation warrants or as finder warrants are not eligible for amendment. The amendments are subject to the final approval of the CSE.About Defence Therapeutics:
Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.For further information:
Defence Therapeutics
Sebastien Plouffe
CEO, Founder and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.comCautionary Statement Regarding "Forward-Looking" InformationThis release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289329
Original: Defence Therapeutics Announces Warrant Terms Amendment

Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000March 9, 2026 3:15 AM
NewsfileMontreal, Quebec--(Newsfile Corp. - March 9, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the closing of a private placement (the "Private Placement") of 17,445,455 units (the "Units") at a price of $0.55 per Unit, for aggregate gross proceeds to Defence of $9,595,000.25. Each Unit is comprised of one common share (each, a "Share") and one common share purchase warrant ("Warrants"). Each Warrant entitles its holder to acquire an additional common share of the Company at a price of $0.65 per share for 24 months following the date of issuance. As previously announced, the Company executed a binding term sheet (the "Term Sheet") with two arm's length institutional investors (collectively, the "Investors") in connection with the Private Placement for aggregate gross proceeds of $6,000,000, pursuant to the terms and conditions of a sharing agreement (the "Sharing Agreement") dated and executed as of March 6, 2026 (the "Closing Date"). For more information, please see the Company's press release dated February 27, 2026. All 10,909,091 Warrants issued pursuant to the Term Sheet are exercisable at an exercise price of $0.65 per Share for a period of 24 months following the Closing Date. The Warrants include an equity blocker provision that prohibits the holder from exercising any portion of the Warrants if such exercise would result in the holder owning more than 9.99% of the Company's outstanding Shares. The Investors received a corporate finance fee of 654,546 Units and a non-refundable deposit of 118,182 Units at the Private Placement price in connection with the Sharing Agreement. Defence intends to use the proceeds from the Private Placement to advance its Antibody Drug Conjugate ("ADC") and Radiopharmaceutical programs, to develop partnerships and for working capital purposes. No finder's fees were paid in connection with the Private Placement. Pursuant to applicable Canadian securities laws and in accordance with the Exchange policies, all securities issued under this Private Placement are subject to applicable resale restrictions under applicable securities laws. The Private Placement closed on March 6, 2026. The Units described herein have not been, and will not be, registered under the U.S. Securities Act or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions there from. This press release does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction.About Defence Therapeutics:
Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.For further information:
Defence Therapeutics
Sebastien Plouffe
CEO, Founder and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.comCautionary Statement Regarding "Forward-Looking" InformationThis release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/287702
Original: Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000

Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in MarchMarch 2, 2026 3:15 AM
NewsfileMontreal, Quebec--(Newsfile Corp. - March 2, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company advancing next-generation therapeutics using its proprietary Accum® platform, today outlined its participation in a series of major international industry events taking place in March 2026.These high-profile meetings will provide Defence with multiple opportunities to advance strategic partnerships, strengthen its global network, and further position Accum® as a differentiated intracellular delivery technology for antibody-drug conjugates (ADCs), radiopharmaceutical conjugates (RDCs), and other complex biologics. BIO-Europe Spring: Primary Focus on Strategic PartnershipsDefence will participate in BIO-Europe Spring (March 23-26, Lisbon, Portugal), the premier global partnering event for the life sciences industry. At BIO-Europe, the Company will prioritize discussions with biopharmaceutical partners seeking to collaborate on enhancing the intracellular delivery and efficacy of their ADC programs using Accum®.DCAT Week: Advancing Biomanufacturing CapabilitiesDefence will also attend DCAT Week (March 23-26, New York), where the Company will focus on strengthening its manufacturing strategy. During DCAT, Defence plans to meet with contract research and manufacturing partners to advance the robust and high-quality biomanufacturing of Accum®, a key operational objective for the Company. Defence has recently become a member of the Drug, Chemical & Associated Technologies Association ("DCAT"), reinforcing its commitment to ensuring the well-characterized, quality-controlled, and commercially ready production of Accum®.Expanding U.S. Presence and Investor EngagementIn parallel, Defence will participate in the South Florida Life Sciences Showcase (March 24, Miami) and FII PRIORITY Miami (March 25-27), supporting the Company's ongoing investor outreach and business development efforts in the United States. Defence has also recently joined BioFlorida, further strengthening its footprint within the Florida life sciences ecosystem."As we engage with partners and industry stakeholders across these key events, our priority is to build meaningful collaborations that support the continued growth and adoption of Accum®," said Sébastien Plouffe, CEO of Defence Therapeutics. "By enabling more efficient intracellular delivery of complex biologics, Accum® has the potential to significantly enhance therapeutic performance and tolerability, positioning the platform as a game-changing solution in the ADC field.". To explore partnering opportunities or schedule a meeting, please contact Defence Therapeutics at info@defencetherapeutics.com.About Defence Therapeutics:Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.For further information:
Defence Therapeutics
Sebastien Plouffe
CEO, Founder and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.comCautionary Statement Regarding "Forward-Looking" InformationThis release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285690
Original: Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March

Defence Therapeutics Announces Private Placement of Units for Proceeds of up to $11 MillionFebruary 27, 2026 5:00 PM
NewsfileMontreal, Quebec--(Newsfile Corp. - February 27, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the launch of a private placement (the "Private Placement") of up to 20,000,000 units (the "Units") at a price of $0.55 per Unit, for aggregate gross proceeds to Defence of up to $11,000,000. Each Unit will be comprised of one common share (each, a "Share") and one common share purchase warrant ("Warrants"). Each Warrant will entitle its holder to acquire an additional common share of the Company at a price of $0.65 per share for 24 months following the date of issuance.The Company has executed a binding term sheet with two arm's length institutional investors (collectively, the "Investors") in connection with the Private Placement for aggregate gross proceeds of $6,000,000 (CAD) (the "Investors' Proceeds"). In connection with the Private Placement, the Investors' Proceeds and the Units will be deposited in escrow in advance of closing pursuant to an escrow agreement (the "Escrow Agreement"). Upon closing, the Units will be released from escrow and delivered to the Investors or as they may direct, and the Investors' Proceeds will be released from escrow and deposited as credit support pursuant to an ISDA Credit Support Annex, and released to the Company in monthly cash tranches of $333,333 (CAD) over an 18-month period (the "Term"), pursuant to the terms and conditions of a sharing agreement (the "Sharing Agreement") to be dated and executed on the closing of the Private Placement. Settlements under the Sharing Agreement shall commence five months after closing. Pursuant to the Sharing Agreement, Shares will be released in equal monthly installments of approximately 606,060 Shares over the 18-month Term, with each release contingent upon the corresponding cash payment being delivered to the Company. The Sharing Agreement shall provide that the Company's economic interest will be determined in 18 monthly settlement tranches as measured against a benchmark price of $0.7332 (CAD) per Share (the "Benchmark Price"). If, at the time of settlement, the settlement price (determined monthly based on a 20-day volume-weighted average trading price of the Company's shares on the CSE) exceeds the Benchmark Price, the Company shall receive more than 100% of the monthly settlement due, on a pro rata basis, with no upper limit on additional proceeds. If the settlement price is below the Benchmark Price, the Company will receive less than 100% of the monthly settlement due, on a pro rata basis. In no event will a decline in the settlement price result in an increase in the number of Shares being issued to the Investors. As a result, the Company may ultimately receive more or materially less than the original proceeds of $6,000,000. The final amount received will depend on the Company's future share price, which is subject to market fluctuations and may vary over time. Accordingly, there is no assurance as to the total amount the Company will receive under the Sharing Agreement. All 10,909,091 Warrants to be issued shall be exercisable at an exercise price of $0.65 (CAD) per Share for a period of 24 months following the date of issuance. The Warrants will include an equity blocker provision that prohibits the holder from exercising any portion of the Warrants if such exercise would result in the holder owning more than 9.99% of the Company's outstanding Shares.The Investors will receive a corporate finance fee of $360,000 (CAD) in connection with the Sharing Agreement, payable in cash or via the issuance of 654,546 Units at the Private Placement price, at the election of the Company (the "Fee").The Company has agreed to pay a non-refundable deposit of $65,000 (CAD) (the "Deposit") upon receipt of approval from the CSE in connection with the Private Placement. The Deposit shall be satisfied by the issuance of 118,182 Units at the Private Placement price. Defence intends to use the proceeds from the Private Placement to advance its Antibody Drug Conjugate ("ADC") and Radiopharmaceutical programs, to develop partnerships and for working capital purposes. The Company may pay a finder's fee in connection with the offering to eligible arm's-length finders in accordance with the policies of the Canadian Securities Exchanges. Pursuant to applicable Canadian securities laws and in accordance with the Exchange policies, all securities issued under this Private Placement will be subject to applicable resale restrictions under applicable securities laws. The closing of the Private Placement is expected on or about March 6, 2026, subject to the approval of the CSE. The Units described herein have not been, and will not be, registered under the U.S. Securities Act or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions there from. This press release does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction.About Defence Therapeutics:
Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.For further information:
Defence Therapeutics
Sebastien Plouffe
CEO, Founder and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com 
www.defencetherapeutics.comCautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285714
Original: Defence Therapeutics Announces Private Placement of Units for Proceeds of up to $11 Million

Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory BoardFebruary 10, 2026 3:15 AM
NewsfileMontreal, Quebec--(Newsfile Corp. - February 10, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, reported on its Scientific Advisory Board ("SAB") meeting held on January 30, 2026, focused on advancing the strategic positioning of Accum® for antibody-drug conjugate ("ADC") applications.The discussion brought together complementary expertise spanning ADC chemistry and development, experimental design and translational science, and value creation and partnering strategy, enabling an in-depth and highly constructive exchange on Accum®'s role in improving intracellular delivery of ADC payloads. The conversation focused on identifying the most critical scientific questions to address, refining development priorities, and aligning data generation with the expectations of future clinical and pharmaceutical partners. "This was an exceptionally valuable discussion that helped us sharpen both our scientific focus and our strategic direction," said Maxime Parisotto, PhD, Chief Scientific Officer of Defence Therapeutics. "The insights shared by our advisors are directly informing how we design our next studies, ensuring that we generate the data that matter most to advance Accum® toward the clinic and position the platform for meaningful partnerships."The discussion benefited from the complementary expertise of Rob Leanna, PhD, whose experience in ADC development, drug-linker chemistry, and clinical advancement was shaped through his long tenure at AbbVie; Danny Chui, PhD, who brought deep insight into ADC design and translational science informed by his significant work at Zymeworks, Abdera Therapeutics, and Kairos Therapeutics; and Brendan Hussey, PhD, who contributed a value-creation and partnering perspective grounded in clinical development, strategy, and capital formation. Together, their input is guiding the next phase of Accum® development as the platform advances toward clinical translation and strategic partnerships.As a result of this multidisciplinary dialogue, Defence Therapeutics is refining its Accum® ADC development roadmap to better align platform capabilities with clinical development requirements and partnering considerations, with the goal of enabling more effective and better-tolerated ADC therapies. This approach reinforces Accum®'s potential as a next-generation intracellular delivery solution for complex biologics. To explore partnering opportunities or schedule a meeting, please contact info@defencetherapeutics.com. About Defence Therapeutics:Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.For further information:Defence Therapeutics
Sebastien Plouffe
CEO, Founder and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.comCautionary Statement Regarding "Forward-Looking" InformationThis release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282529
Original: Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board

Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery PlatformFebruary 4, 2026 3:15 AM
NewsfileMontreal, Quebec--(Newsfile Corp. - February 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced that it will present at World ADC Europe?2026, taking place February 23–26, 2026, in London, UK. Defence will showcase its proprietary Accum® platform, a breakthrough intracellular delivery technology designed to actively transport biologic payloads to their intended intracellular and nuclear targets, unlocking the full potential of antibody-drug conjugates ("ADCs") and other complex cancer biologics by increasing intracellular potency and reducing the doses required to achieve therapeutic efficacy. "At Defence, our mission is to transform advanced biologics into safer, more effective first-line cancer therapies through precision intracellular delivery," said Sébastien Plouffe, CEO of Defence Therapeutics. "World ADC Europe is a premier global forum to engage with innovators and potential partners who share our vision of a future where every cancer therapy reaches its full potential." This announcement is being made on World Cancer Day, underscoring Defence's commitment to accelerating next-generation cancer therapies that address critical unmet medical needs. "On World Cancer Day, we are reminded of the urgency to bring smarter, more precise cancer treatments to patients," added Mr. Plouffe. "Accum® has the potential to help cancer therapies reach their full potential and deliver better outcomes for patients." At the conference, Defence aims to engage with pharmaceutical and biotechnology companies and advance strategic partnering discussions around co-developing Accum®-enabled ADCs and precision oncology biologics, leveraging Accum® to enhance intracellular delivery and therapeutic performance. To explore partnering opportunities or schedule a meeting, please contact info@defencetherapeutics.com. About Defence Therapeutics:
Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.For further information:
Defence Therapeutics
Sebastien Plouffe
CEO, Founder and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com 
www.defencetherapeutics.comCautionary Statement Regarding "Forward-Looking" InformationThis release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282380
Original: Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform

Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical PipelineJanuary 28, 2026 1:40 PM
NewsfileMontreal, Quebec--(Newsfile Corp. - January 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced the strengthening of its long-standing collaboration with Canadian Nuclear Laboratories ("CNL") as part of its strategic effort to accelerate and expand its proprietary radiopharmaceutical program.Defence has been collaborating with CNL on the development of an Accum®-enhanced radio-immunoconjugate program. This program is now approaching a key inflection point, with critical results being generated by both lab teams on this program that are intended to support candidate selection and enable preparation for first-in-human clinical studies.Based on the exciting traction on the lead program, Defence and CNL are expanding their collaboration to initiate multiple other radioisotopes programs with Defence's proprietary Accum®, positioning the Company to rapidly expand its radiopharmaceutical portfolio as new data and strategic priorities emerge.Radiopharmaceutical therapies require precise intracellular and nuclear localization to maximize efficacy, as radioactive payloads must reach the vicinity of the cell nucleus to induce lethal DNA damage. Defence's proprietary Accum® platform enables active intracellular and nuclear transport, unlocking the full therapeutic potential of targeted radiotherapies while increasing potency and reducing toxicity."This collaboration with CNL has become a cornerstone of our radiopharmaceutical strategy," said Sébastien Plouffe, CEO of Defence Therapeutics. "Radiopharmaceuticals now represent one of our top development priorities alongside our ADC program. By deepening our work with CNL and leveraging their world-class nuclear science expertise, we are building a strong, proprietary pipeline in this space and accelerating our path toward the clinic.""We have worked in close collaboration with Defence on their flagship program, delivering the technical results they require, and we are proud to contribute meaningfully to the advancement of their radiopharmaceutical pipeline," said Dr. Monica Regalbuto, Vice-President, Science & Technology at CNL. "We look forward to contributing our nuclear science expertise to help advance these programs toward the clinic."This collaboration further strengthens Defence's position in precision intracellular drug delivery and radiopharmaceutical development, supporting its strategy to transform advanced biologics into safer, more effective first-line cancer therapies. To learn more or explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.About Defence Therapeutics:Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.About Canadian Nuclear Laboratories:As Canada's premier nuclear science and technology laboratory and working under the direction of Atomic Energy of Canada Limited (AECL), CNL is a world leader in the development of innovative nuclear science and technology products and services. Guided by an ambitious corporate strategy known as Vision 2030, CNL fulfills three strategic priorities of national importance - restoring and protecting the environment, advancing clean energy technologies, and contributing to the health of Canadians. By leveraging the assets owned by AECL, CNL also serves as the nexus between government, the nuclear industry, the broader private sector and the academic community. CNL works in collaboration with these sectors to advance innovative Canadian products and services towards real-world use, including carbon-free energy, cancer treatments and other therapies, non-proliferation technologies and waste management solutions.For further information:
Defence Therapeutics
Sebastien Plouffe
CEO, Founder and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.comCanadian Nuclear Laboratories
Philip Kompass
Director, Corporate Communications
1-866-886-2325
media@cnl.caCautionary Statement Regarding "Forward-Looking" InformationThis release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/281929
Original: Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline

Why are there no trades here ?

Thank you !

Great news today !

Get in KITL .08-.10 news will be poppin

Need more volume for Poppin action

Looking for FDA Poppin news

KITL news going to be poppin

Seems to be a very interesting stock.